Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or
Does the drug dupilumab help patients with alopecia areata?
Basic Study Information
Purpose:Location: UR Dermatology at College Town
Alopecia Areata is patchy baldness on the scalp. This trial will enroll patients
with moderate to severe alopecia areata (affecting more than 50% of the scalp) at
the time of screening. Potential participants must have evidence of hair regrowth
within the last 7 years of their last episode of hair loss; and have screening IgE
≥ 200 and/or have personal and/or familial history of atopy. Potential participants
will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks,
with all subjects completing participation through Week 48 receiving an additional
48 weeks of dupilumab (through Week 96).
Study Reference #: STUDY00007640
Lead Researcher (Principal Investigator)
Mary Gail Mercurio
Study Contact InformationStudy Coordinator: Alicia Papalia
Phone: (585) 273-4195
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search